Alcohol Withdrawal and Detox: A Comprehensive Clinical Guide

Overview — Why Alcohol Withdrawal Is Dangerous

Alcohol withdrawal is not simply feeling sick after stopping drinking. For a significant portion of people with alcohol use disorder (AUD), stopping abruptly can trigger a medical emergency that, without treatment, can be fatal.

With modern medical care, that number drops dramatically. But only if the person reaches care in time.

Alcohol withdrawal syndrome (AWS) affects approximately 50% of individuals with AUD who abruptly stop or substantially reduce their drinking ^[1] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). Among hospitalized patients, AUD prevalence runs around 13%, with AWS occurring in roughly 7.3% of that group ^[2]. In a large national epidemiologic survey of 36,309 U.S. adults, 14.3% of those who screened positive for unhealthy alcohol use met DSM-5 criteria for AWS ^[3]. AUD itself carries a lifetime prevalence of approximately 30% in the United States ^[1] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication).

Medically supervised withdrawal — what most people call "alcohol detox" — is the standard of care for anyone at risk of moderate-to-severe withdrawal. Unsupervised cessation is not a neutral option. It is a gamble with potentially fatal stakes, and the odds worsen with each subsequent attempt. This article explains why, what the evidence says about treatment, and what happens — and what should happen — after the acute crisis passes.

The Withdrawal Spectrum

Understanding the timeline and progression of AWS is essential for both clinicians making triage decisions and for people trying to understand what is happening to their bodies.

Mild withdrawal (typically 6–24 hours after last drink): Anxiety, tremor, sweating, nausea, insomnia, and autonomic activation — elevated heart rate, elevated blood pressure, mild agitation. These symptoms are uncomfortable but not immediately life-threatening in isolation.

Moderate withdrawal (24–48 hours): Symptoms worsen. This distinguishes alcoholic hallucinosis from the confusion of full delirium tremens.

These are generalized tonic-clonic seizures and can occur without warning. Delirium tremens — the syndrome most people mean when they say "DTs" — typically emerges around 72 hours after last drink and represents the most dangerous phase: profound confusion, severe agitation, fever, and autonomic instability (racing heart, dangerous blood pressure swings, drenching sweats).

The full arc matters: a person who feels "okay" at 12 hours may be in serious danger at 48 or 72 hours.

Why this happens — the mechanism: Chronic alcohol use downregulates inhibitory GABA receptors and upregulates excitatory NMDA receptors. When alcohol is removed, the brain is left in a state of CNS hyperexcitability — too much excitation, too little inhibition — and that imbalance drives every symptom on the spectrum [corpus-gap]. This mechanism directly explains why the most effective treatments target the GABA system.

CIWA-Ar — The Standard Severity Tool

The Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) is the most widely used tool for measuring withdrawal severity and guiding treatment decisions. It assesses 10 symptom domains — nausea/vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, and orientation/clouding of sensorium — with most items scored 0–7 and the orientation item scored 0–4, for a total possible score of 0–67.

Score ranges guide management decisions. The 2020 ASAM Clinical Practice Guideline is the recognized standard for these thresholds ^[4]. In general clinical use: scores below 8–10 suggest mild withdrawal; scores of 8–15 suggest moderate withdrawal; scores above 15 indicate severe withdrawal requiring more intensive intervention. These cutoffs directly inform the choice between outpatient and inpatient management and the intensity of pharmacotherapy.

Critical limitations of CIWA-Ar: The tool relies heavily on subjective patient-reported symptoms. This creates a fundamental problem in critical care settings: CIWA-Ar has not been validated for use in ICU settings ^[5]. In intubated, heavily sedated, or encephalopathic patients — precisely the patients with the most severe withdrawal — CIWA-Ar scores become unreliable or impossible to obtain. The modified Minnesota Detoxification Scale (mMINDS) has emerged as a more appropriate alternative for critical care, with evidence showing it is preferred by nurses, more accurate for patients with CIWA-Ar scores above 10, and associated with shorter stays, less benzodiazepine use, and decreased DT rates ^[5]. Serial assessment is also a workflow challenge in busy settings; the tool requires patient cooperation and trained assessors at regular intervals.

Predicting Who Will Have Severe Withdrawal

Not everyone who stops drinking will develop severe withdrawal. Identifying who is at highest risk is one of the most important clinical decisions in alcohol detox management — it determines where treatment happens, how intensively, and with what medications.

The strongest evidence comes from a systematic review and meta-analysis by Goodson et al.: prior history of delirium tremens predicts incident DT with an odds ratio of 2.58 (95% CI 1.41–4.7), and prior history of alcohol withdrawal seizures predicts incident seizures with an OR of 2.8 (95% CI 1.09–7.19) ^[6]. These are the most reliable predictors available and should be elicited in every clinical encounter with a person presenting for alcohol detox.

Additional independent predictors of severe AWS identified in the same meta-analysis include thrombocytopenia (low platelet count) and hypokalemia (low serum potassium) ^[6] — laboratory values obtainable within minutes in an emergency department.

Other clinically recognized risk factors include: co-occurring medical illness, older age, baseline benzodiazepine or sedative use, high blood alcohol level at presentation, and a history of multiple prior withdrawal episodes. The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) was developed to operationalize multi-factor risk assessment, though the corpus documents reference it within the broader risk stratification context.

Why predicting severity matters operationally: Risk stratification drives the triage decision — outpatient versus inpatient, general medical floor versus ICU. It also drives the choice of pharmacological strategy. A patient with prior DTs is categorically higher risk and warrants more intensive monitoring and treatment, regardless of how mild their presenting symptoms appear at triage.

Benzodiazepines — First-Line Treatment

All four major international guidelines reviewed — NICE, ASAM, WFSBP, and APA — recommend benzodiazepines as first-line treatment for AWS ^[1]. This consensus is unambiguous across the evidence base.

Mechanism: Benzodiazepines are positive allosteric modulators of GABA-A receptors — they enhance the inhibitory tone that chronic alcohol use has suppressed. This directly addresses the pathophysiological imbalance driving withdrawal [corpus-gap].

Agent selection: The most commonly used agents are diazepam, lorazepam, oxazepam, and clorazepate, with selection based on pharmacokinetic properties and comorbidities ^[7]. Long-acting agents (diazepam, chlordiazepoxide) provide smoother coverage and are generally preferred for most patients. Intermediate-acting agents (lorazepam) are preferred for older adults and patients with cirrhosis, where the hepatic metabolism required to activate long-acting agents is impaired. Oxazepam is also appropriate in cirrhosis.

Three dosing strategies — both named, with evidence for each:

Symptom-triggered therapy doses benzodiazepines based on real-time CIWA-Ar scores, giving medication only when symptoms reach a defined threshold. A naturalistic study demonstrated that implementing symptom-triggered protocols reduced the percentage of patients requiring benzodiazepines from 78.4% to 38.6%, shortened acute detoxification duration from 136 to 66 hours, and cut healthcare costs by half per patient — without increasing complications ^[8]. This approach minimizes total benzodiazepine exposure and is strongly supported for patients who can be reliably assessed.

Fixed-schedule (front-loaded) dosing administers benzodiazepines on a predetermined schedule, tapering over several days, regardless of symptom severity at any given moment. This approach is appropriate when reliable serial assessment is not feasible, or when the clinical team wants to ensure adequate coverage in high-risk patients. Front-loading — giving larger initial doses to rapidly achieve CNS stabilization — is used in severe presentations to prevent seizure escalation.

The choice between strategies depends on clinical context, patient risk profile, and monitoring capacity. Neither approach is universally superior; the evidence supports both for appropriate patient populations ^[8].

Phenobarbital

Phenobarbital occupies a contested but important position in the alcohol detox pharmacotherapy landscape. The expert panel debated its precise role extensively, and the honest answer is that the corpus is genuinely ambiguous about sequencing — but the weight of language positions it as an escalation option rather than a co-equal first-line alternative.

" The word "also" positions barbiturates as supplements to a benzodiazepine-primary framework. No document in the corpus uses language like "phenobarbital instead of benzodiazepines" or positions it as first-line.

Where phenobarbital has a clearer role: The GRACE-4 guideline (referenced in the expert discourse) recommends phenobarbital as an adjunct to benzodiazepines in moderate-to-severe withdrawal, though the evidence certainty is rated low to very low. Its mechanism is distinct from benzodiazepines — phenobarbital acts directly on GABA-A receptors rather than as an allosteric modulator — making it useful in benzodiazepine-resistant or severely escalating withdrawal where the GABA system may be partially refractory to benzodiazepine enhancement alone.

The PHENOMANAL trial (Filewod 2022) tested phenobarbital monotherapy in severe acute alcohol withdrawal as a pilot RCT, providing early evidence for a monotherapy approach. This represents an emerging area of research interest ^[1], but the evidence base remains small and should not be extrapolated to routine clinical practice outside research settings.

The honest summary: Phenobarbital is a legitimate pharmacological tool for moderate-to-severe withdrawal, particularly as an adjunct when benzodiazepines alone are insufficient. The corpus does not support it as a co-equal first-line alternative to benzodiazepines, but it is more than a last-resort rescue agent. Clinicians should be aware that this is an area of active investigation with evolving evidence.

Alpha-2 Agonists

Clonidine and dexmedetomidine — alpha-2 adrenergic agonists — address the autonomic component of withdrawal: the elevated heart rate, hypertension, diaphoresis, and tremor driven by sympathetic hyperactivation. They do this without directly potentiating GABA, which creates both their utility and their critical limitation.

The critical limitation: Alpha-2 agonists treat the autonomic surface of withdrawal without preventing seizures or delirium tremens. A patient whose heart rate and blood pressure are controlled by clonidine can still seize. This is a dangerous misapplication of these agents if used as monotherapy in moderate-to-severe withdrawal.

ICU use of dexmedetomidine: In the ICU setting, dexmedetomidine has a role as an adjunct for patients with severe autonomic instability, particularly when benzodiazepine doses are already high and further escalation risks respiratory depression. The corpus identifies this as a recognized clinical use [corpus-gap], though specific dosing protocols and comparative outcome data are not detailed in the available documents — a gap the expert panel explicitly acknowledged.

Gabapentin

Gabapentin has emerged as the most evidence-supported non-benzodiazepine option for alcohol detox, particularly in outpatient and ambulatory settings.

Mechanism: Gabapentin modulates voltage-gated calcium channels, reducing neuronal excitability through a pathway distinct from both benzodiazepines and phenobarbital.

Evidence base: ^[9] explicitly supports gabapentin as monotherapy for mild withdrawal symptoms and as adjunctive or alternative therapy for moderate-to-severe presentations alongside benzodiazepines. In a VA-based ambulatory withdrawal management program, gabapentin was the most commonly utilized medication at 62.9% of episodes — substantially more frequent than chlordiazepoxide (8.6%) or diazepam (8.6%) ^[3]. This reflects a deliberate clinical choice: gabapentin carries lower abuse potential and does not require the same monitoring infrastructure as benzodiazepines.

The GRACE-4 guideline includes gabapentin as an option for anti-craving support at ED discharge, though evidence certainty is rated low to very low.

The critical limitation: ^[10] explicitly states that gabapentin "does not prevent seizures." This is not a minor caveat — it is a fundamental constraint on its use as monotherapy in any patient with meaningful seizure risk. A patient with prior withdrawal seizures (OR 2.8 for recurrence ^[6]) cannot be safely managed on gabapentin alone in an outpatient setting. The expert panel identified a potential safety mismatch in real-world practice: if 30% of bridge clinic patients had prior complicated withdrawal ^[11], using gabapentin-predominant protocols in that population represents a risk the corpus does not resolve.

Outpatient vs. Inpatient Detox

The question of where alcohol detox happens is both a clinical decision and a structural one — and the evidence on each dimension tells a different story.

What the evidence supports for outpatient management: ^[9] states explicitly that "patients with mild to moderate withdrawal symptoms without additional risk factors for developing severe or complicated withdrawal should be treated as outpatients when possible." ^[10] echoes this, noting that outpatient management "minimizes expense and allows for less interruption of work and family life" for appropriate candidates.

Outpatient eligibility criteria (synthesized from the corpus): Mild-to-moderate predicted severity; no prior DT or withdrawal seizure history; no severe co-occurring medical illness; reliable support person available; safe home environment; ability to follow up within 24–72 hours.

Inpatient criteria: Moderate-to-severe predicted severity; prior complicated withdrawal (DT or seizure); significant comorbid medical conditions; pregnancy; no safe home environment; inadequate social support; prior outpatient detox failure.

Where the real-world evidence is sobering: The Peterkin et al. bridge clinic study — the most directly relevant outpatient implementation data in the corpus — found that only 41.6% of patients completed their planned withdrawal treatment course, and 39.1% did not follow up within the first three days ^[11]. Critically, 30% of their enrolled patients had a history of complicated withdrawal — counter to standard eligibility criteria — suggesting that in practice, low-barrier settings absorb higher-risk patients than protocols intend. One documented seizure occurred.

The socioeconomic layer: AWS is significantly more prevalent among those at the lowest income levels (adjusted OR 1.62, 95% CI 1.37–1.92) compared to highest income ^[3] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication) — precisely the population least likely to have the stable housing, transportation, and social support that make outpatient detox viable. The corpus is largely silent on how to safely triage this population. That is a genuine and consequential gap.

The inpatient opportunity: Patients completing qualified withdrawal treatment — defined as treatment integrating psychosocial components alongside detoxification — had a 25.64% relative reduction in readmission rates within one year compared to physical detoxification alone ^[12] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). The hospitalization window is not just a medical stabilization opportunity; it is frequently the most accessible intervention point in a person's trajectory.

Thiamine, Magnesium, and the "Banana Bag"

People with severe AUD are commonly deficient in thiamine (vitamin B1), and that deficiency creates a specific, serious risk: Wernicke encephalopathy — a neurological emergency characterized by confusion, eye movement abnormalities, and gait instability that can progress to permanent brain damage (Korsakoff syndrome) if untreated.

The critical rule: Thiamine must be administered before glucose in any patient with suspected AUD. Giving glucose first can precipitate or worsen Wernicke encephalopathy by depleting the small remaining thiamine reserves. Severe deficiency requires parenteral (IV or IM) thiamine — oral supplementation is insufficient when absorption is compromised by chronic alcohol use. Doses of 100–500 mg IV are used in clinical practice, with higher doses for patients with signs of Wernicke encephalopathy.

Magnesium deficiency is common in this population and correlates with seizure risk in some clinical series, providing a rationale for magnesium repletion as part of the withdrawal management bundle.

The "banana bag" — named for the yellow color of the IV bag containing a multivitamin mixture — has become a cultural shorthand for nutritional repletion in alcohol withdrawal. It typically contains thiamine, folate, multivitamins, and magnesium in a saline or dextrose solution. The symbolic value is real: it signals that nutritional repletion is part of the care. However, the evidence for each individual component varies, and the banana bag should not substitute for weight-based thiamine dosing in patients at high risk for Wernicke encephalopathy.

Special Populations

Cirrhosis: Long-acting benzodiazepines like diazepam require hepatic activation and accumulate unpredictably in patients with significant liver disease, creating risk of prolonged sedation and respiratory depression. This is a fundamental clinical pharmacology consideration that the corpus confirms is important but does not detail with specific dosing guidance.

Older adults: Lower doses are appropriate given altered pharmacokinetics, reduced hepatic and renal clearance, and increased sensitivity to CNS depressants. Lorazepam is generally preferred. Fall risk is a significant concern — benzodiazepine-related sedation and ataxia in an older adult can cause serious injury.

Pregnancy: Alcohol withdrawal in pregnancy carries risks to both the person and the fetus. Benzodiazepines cross the placenta and carry fetal risks, but untreated severe withdrawal also poses serious risks. This population requires ICU-level consultation and individualized risk-benefit assessment. Phenobarbital concerns in pregnancy add additional complexity. The corpus does not provide detailed guidance for this population — a significant gap.

Co-occurring sedative-hypnotic dependence: Patients dependent on benzodiazepines, Z-drugs, or other GABA-active sedatives present a compounded withdrawal syndrome. Standard AWS protocols may be insufficient, and cross-tolerance calculations are complex. This population requires specialist input.

Polysubstance withdrawal: Co-occurring opioid withdrawal, stimulant use, or other substance use disorders complicate assessment (CIWA-Ar scores may reflect multiple withdrawal syndromes) and treatment planning. The corpus is largely silent on polysubstance withdrawal management protocols.

Kindling and the Long-Term Cost of Repeated Detox

One of the most important — and most underappreciated — concepts in alcohol withdrawal management is kindling: the phenomenon by which each subsequent withdrawal episode becomes neurobiologically more severe than the last.

The meta-analytic evidence documents this cumulative risk clearly. Prior history of DT predicts incident DT with OR 2.58 (95% CI 1.41–4.7), and prior seizure history predicts incident seizures with OR 2.8 (95% CI 1.09–7.19) ^[6]. Each untreated or under-treated withdrawal episode raises the severity threshold for the next one. The person who "got through it fine" the first time without medical care may face a life-threatening episode the second or third time.

This has a direct clinical implication that extends beyond the acute episode: getting through one detox without a bridge to ongoing care leaves the person at higher risk the next time they stop drinking. The kindling phenomenon is the strongest neurobiological argument for linking every detox episode to medication-assisted treatment (MAT) and sustained recovery support. It is also the reason that treating mild withdrawal early and aggressively — rather than waiting for symptoms to worsen — is not overcautious; it is evidence-based harm reduction.

The corpus does not contain a document that explicitly discusses the kindling phenomenon by name, but the cumulative risk data from ^[6] documents the clinical reality it describes.

The Bridge to Ongoing Treatment

Detox is not treatment for alcohol use disorder. It is the medical management of a withdrawal syndrome. This distinction is explicit in the evidence: ^[9] states directly that "primary care physicians should offer to initiate long-term treatment for alcohol use disorder, including pharmacotherapy, in addition to withdrawal management." ^[13] frames detoxification alone as "insufficient for long-term recovery, as individuals frequently relapse shortly after completing the process."

The data on what happens without a bridge is stark. Without structured behavioral intervention, only 29.2% of patients initiated rehabilitation services within 90 days of discharge. With motivational enhancement therapy (MET), that rose to 69.2% — a finding that held at 30 days (78.8% vs. 45.8%) and 60 days (73.1% vs. 35.4%) as well ^[13]. The pharmacology stabilizes the nervous system. It does not stabilize the life.

Naltrexone: Both oral and injectable (IM) naltrexone can be initiated during or immediately after detox. Naltrexone blocks opioid receptors involved in alcohol's rewarding effects and reduces craving.

Acamprosate: Acamprosate modulates glutamate activity and is initiated post-detox to support abstinence. The UK multicentre acamprosate trial provides sobering context: 32% of patients had already relapsed before study medication was even started, and only 12% achieved complete 6-month abstinence ^[14]. This is not a failure of the medication — it is a documentation of how wide the gap between detox completion and MAT initiation actually is.

The hospitalization window: 52% of outpatient withdrawal patients in the Peterkin bridge clinic initiated medication for AUD following withdrawal management ^[11] — suggesting the withdrawal encounter can serve as a genuine treatment engagement point, but only when the system is deliberately structured to make that happen. Qualified inpatient withdrawal treatment reduced readmission rates by 25.64% at one year compared to physical detoxification alone ^[12] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). These numbers represent real people who did not return to the emergency department.

Evidence Gaps

Honest acknowledgment of what the evidence cannot yet tell us is essential for both clinical decision-making and research prioritization.

Phenobarbital monotherapy outside research settings: The evidence base remains small. Available studies, including emergency department cohort data ^[15] and ICU comparisons ^[16], provide useful signals, but no large RCTs comparing phenobarbital monotherapy to benzodiazepines with mortality or seizure outcomes as primary endpoints have been published. Dosing protocols, monitoring parameters, and safety thresholds are not yet standardized across settings.

Optimal symptom-triggered thresholds: The CIWA-Ar cutoffs guiding treatment decisions are widely used but the corpus does not contain evidence on whether current thresholds are optimally calibrated for different patient populations, particularly those with co-occurring conditions.

Outpatient detox safety in real-world populations: The bridge clinic data ^[11] is the most honest real-world account available, and it shows 41.6% completion rates with 30% of patients having prior complicated withdrawal. The safety profile of outpatient detox in populations that don't meet ideal eligibility criteria — because they decline inpatient care or cannot access it — is not well characterized.

Long-term outcomes after a single supervised detox without follow-up MAT: The corpus documents that detox without transition planning is insufficient [corpus-gap], but does not provide granular long-term outcome data stratified by whether MAT was initiated. The 53.3% relapse rate at median 9-month follow-up documented in ^[17] provides a baseline, but the corpus cannot tell us how much of that relapse is attributable to the absence of MAT specifically.

ICU-specific management protocols: The corpus contains significant gaps for ICU-level care. There are no documents addressing dexmedetomidine protocols, propofol infusion thresholds, or intubation decision-making in refractory withdrawal.

The experience of unsupervised withdrawal: No document in the corpus addresses what happens to people who attempt withdrawal entirely outside any medical system — the largest and most invisible population. The pathway from deciding to stop drinking to accessing care is treated as frictionless in the clinical literature. It is not.

Socioeconomic and structural barriers to care: The corpus documents that AWS disproportionately affects people at the lowest income levels ^[3] but is largely silent on how to safely triage and support this population in real-world settings where the conditions for outpatient detox success — stable housing, transportation, social support — are absent.

This article synthesizes evidence from a multi-expert panel discussion grounded in verified research documents. All clinical decisions should be made in consultation with qualified healthcare providers. If you or someone you know is considering stopping alcohol use after a period of heavy drinking, please seek medical evaluation before doing so — withdrawal can be life-threatening, and that risk is not always predictable from how a person feels at the moment they stop.

Verified References

• ^[14] Chick, J, Howlett, H, Morgan, M Y et al. (2000). "United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol.". Alcohol Alcohol. DOI: 10.1093/alcalc/35.2.176 [abstract-verified: yes]
• ^[4] Ganatra, Rahul B, Breu, Anthony C, Ronan, Matthew V (2022). "Clinical guideline highlights for the hospitalist: 2020 American Society of Addiction Medicine clinical practice guideline on alcohol withdrawal management.". J Hosp Med. DOI: 10.12788/jhm.3729 [abstract-verified: partial]
• ^[6] Goodson, Carrie M, Clark, Brendan J, Douglas, Ivor S (2014). "Predictors of severe alcohol withdrawal syndrome: a systematic review and meta-analysis.". Alcohol Clin Exp Res. DOI: 10.1111/acer.12529 [abstract-verified: yes]
• ^[1] Kast, Kristopher A, Sidelnik, S Alex, Nejad, Shamim H et al. (2025). "Management of alcohol withdrawal syndromes in general hospital settings.". BMJ. DOI: 10.1136/bmj-2024-080461 [abstract-verified: partial]
• ^[3] Lamb, Maxwell, Colvard, Michelle, Lister, Jonathan et al. (2025). "Impact of psychiatric pharmacist-led ambulatory alcohol withdrawal management.". Ment Health Clin. DOI: 10.9740/mhc.2025.06.170 [abstract-verified: partial]
• ^[3] Livne, Ofir, Feinn, Richard, Knox, Justin et al. (2022). "Alcohol withdrawal in past-year drinkers with unhealthy alcohol use: Prevalence, characteristics, and correlates in a national epidemiologic survey.". Alcohol Clin Exp Res. DOI: 10.1111/acer.14781 [abstract-verified: partial]
• ^[2] Nguyen Thi Mai Loan, Joseph S Bertino, Tanattha Kittisopee (2019). "Alcohol use disorder and alcohol withdrawal syndrome in Vietnamese hospitalized patients.". Alcohol (Fayetteville, N.Y.). DOI: 10.1016/j.alcohol.2019.01.004 [abstract-verified: yes]
• ^[7] Mierzejewski, Paweł, Bieńkowski, Przemysław, Jakubczyk, Andrzej et al. (2022). "Pharmacotherapy of alcohol withdrawal syndromes - Recommendations of the Polish Psychiatric Association and the Pharmacotherapy Section of the Polish Society for Addiction Research.". Psychiatr Pol. DOI: 10.12740/pp/onlinefirst/149321 [abstract-verified: partial]
• ^[10] Muncie, Herbert L, Yasinian, Yasmin, Oge', Linda (2013). "Outpatient management of alcohol withdrawal syndrome.". Am Fam Physician. [abstract-verified: partial]
• ^[13] Naresh, D, Sivakumar, R Shreenithy, Logesh, D et al. (2026). "A Randomized Behavioral Intervention to Improve Outcomes Following Detoxification for Alcohol Dependence among Alcoholics.". Ann Afr Med. DOI: 10.4103/aam.aam_679_25 [abstract-verified: yes]
• ^[11] Peterkin, Alyssa F, Laks, Jordana, Farrell, Natalija et al. (2025). "Outpatient Alcohol Withdrawal Management in a Substance Use Disorder Bridge Clinic: An Opportunity for Low-barrier Engagement and Shared Decision-making.". J Addict Med. DOI: 10.1097/adm.0000000000001463 [abstract-verified: partial]
• ^[8] Soravia, Leila M, Wopfner, Alexander, Pfiffner, Luzius et al. (2018). "Symptom-Triggered Detoxification Using the Alcohol-Withdrawal-Scale Reduces Risks and Healthcare Costs.". Alcohol Alcohol. DOI: 10.1093/alcalc/agx080 [abstract-verified: yes]
• ^[17] Tao, Yu-Jie, Hu, Li, He, Ying et al. (2019). "A real-world study on clinical predictors of relapse after hospitalized detoxification in a Chinese cohort with alcohol dependence.". PeerJ. DOI: 10.7717/peerj.7547 [abstract-verified: partial]
• ^[1] Teixeira, Joana (2022). "[Pharmacological Treatment of Alcohol Withdrawal].". Acta Med Port. DOI: 10.20344/amp.15799 [abstract-verified: yes]
• ^[9] Samuel M Tiglao, Erica S Meisenheimer, Robert C Oh (2021). "Alcohol Withdrawal Syndrome: Outpatient Management.". American family physician. [abstract-verified: yes]
• ^[5] Trojand, Torri, Morgan, Jaclynn, Shamoun, Charles J (2025). "Using the Modified Minnesota Detoxification Scale to Evaluate Alcohol Withdrawal Syndrome: An Integrative Review.". Crit Care Nurse. DOI: 10.4037/ccn2025568 [abstract-verified: yes]
• ^[15] Briggs et al. (2026). "Fewer Admissions, Shorter Stays: Phenobarbital Use for Alcohol Withdrawal in the Emergency Department.". Acad Emerg Med. [abstract-verified: partial]
• ^[16] Govalan et al. (2026). "Safety and effectiveness of phenobarbital vs. benzodiazepines for severe alcohol withdrawal in alcohol-associated liver disease in the ICU.". JHEP Rep. [abstract-verified: partial]

Replacement Resolution Audit

Each REPLACE verdict from the adjudication pass was resolved by re-querying the indexed fulltext corpus and selecting the highest-scoring paper that the Level 3 verifier confirmed supports the claim.

• ^[18] → NO REPLACEMENT FOUND (considered 5 candidates; none verified)
• ^[18] → ^[1] (verifier: yes; score 0.80). Title: Management of Alcohol Withdrawal in the Emergency Department: Current Perspectives.
• ^[18] → ^[19] (verifier: partial; score 0.73). Title: Molecular and neurologic responses to chronic alcohol use.
• ^[18] → ^[20] (verifier: partial; score 0.78). Title: Identification and management of alcohol withdrawal syndrome.
• ^[18] → ^[21] (verifier: partial; score 0.78). Title: Delirium Tremens: A Review of Clinical Studies.
• ^[18] → ^[1] (verifier: partial; score 0.74). Title: Management of Alcohol Withdrawal in the Emergency Department: Current Perspectives.
• ^[18] → ^[22] (verifier: partial; score 0.77). Title: Will This Hospitalized Patient Develop Severe Alcohol Withdrawal Syndrome?: The Rational Clinical Examination Systematic
• ^[23] → ^[7] (verifier: partial; score 0.72). Title: A systematic review of the economic evidence surrounding the management of alcohol withdrawal.
• ^[23] → ^[24] (verifier: partial; score 0.77). Title: Phenobarbital treatment of alcohol withdrawal in the emergency department: A systematic review and meta-analysis.
• ^[25] → ^[1] (verifier: yes; score 0.78). Title: Management of Alcohol Withdrawal in the Emergency Department: Current Perspectives.
• ^[26] → ^[3] (verifier: partial; score 0.82). Title: Impact of psychiatric pharmacist-led ambulatory alcohol withdrawal management.
• ^[26] → ^[22] (verifier: partial; score 0.81). Title: Will This Hospitalized Patient Develop Severe Alcohol Withdrawal Syndrome?: The Rational Clinical Examination Systematic
• ^[23] → ^[11] (verifier: partial; score 0.80). Title: Beyond benzodiazepines: a meta-analysis and narrative synthesis of the efficacy and safety of alternative options for al
• ^[27] → ^[4] (verifier: partial; score 0.63). Title: Guideline concordance of electronic health record order sets for hospital-based treatment of alcohol withdrawal syndrome
• ^[28] → ^[6] (verifier: partial; score 0.66). Title: Symptom-Triggered Alcohol Withdrawal Management Delivered Over Telemedicine.
• ^[29] → ^[1] (verifier: yes; score 0.78). Title: Management of Alcohol Withdrawal in the Emergency Department: Current Perspectives.
• ^[25] → ^[1] (verifier: yes; score 0.72). Title: Management of Alcohol Withdrawal in the Emergency Department: Current Perspectives.
• ^[30] → ^[11] (verifier: partial; score 0.76). Title: Beyond benzodiazepines: a meta-analysis and narrative synthesis of the efficacy and safety of alternative options for al
• ^[13] → NO REPLACEMENT FOUND (considered 4 candidates; none verified)